Strax

Autospela

Defining Progression in Metastatic Kidney Cancer

3 Visningar • 06/26/23
Dela med sig
Bädda in
administrator
administrator
Prenumeranter
0

Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.

Visa mer
0 Kommentarer sort Sortera efter
Facebook-kommentarer

Strax

Autospela